Healthequity (HQY) Rating Lowered to Sell at BidaskClub

Healthequity (NASDAQ:HQY) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Thursday.

Several other analysts have also recently commented on HQY. Chardan Capital upped their target price on Healthequity from $58.00 to $62.00 and gave the company a “buy” rating in a report on Wednesday. Cantor Fitzgerald reiterated a “buy” rating and issued a $56.00 target price on shares of Healthequity in a report on Tuesday. Robert W. Baird reiterated a “hold” rating on shares of Healthequity in a report on Thursday, September 21st. Oppenheimer restated a “buy” rating and set a $61.00 price target on shares of Healthequity in a report on Wednesday, September 6th. Finally, Zacks Investment Research cut Healthequity from a “buy” rating to a “hold” rating in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $58.33.

Healthequity (NASDAQ HQY) traded up $1.87 during trading on Thursday, hitting $47.88. The stock had a trading volume of 1,084,708 shares, compared to its average volume of 529,745. Healthequity has a one year low of $37.62 and a one year high of $55.31. The firm has a market capitalization of $2,933.10, a P/E ratio of 69.27, a P/E/G ratio of 2.13 and a beta of 1.74.

Healthequity (NASDAQ:HQY) last announced its earnings results on Tuesday, December 5th. The company reported $0.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.04. Healthequity had a return on equity of 15.03% and a net margin of 21.08%. The business had revenue of $56.80 million for the quarter, compared to analysts’ expectations of $55.27 million. During the same period in the prior year, the business posted $0.10 earnings per share. The firm’s revenue was up 31.0% on a year-over-year basis. analysts forecast that Healthequity will post 0.7 EPS for the current fiscal year.

In related news, insider Stephen Neeleman sold 8,500 shares of the stock in a transaction on Friday, September 15th. The stock was sold at an average price of $45.24, for a total value of $384,540.00. Following the transaction, the insider now directly owns 1,000 shares in the company, valued at approximately $45,240. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Frank Medici sold 316,644 shares of the stock in a transaction on Monday, October 9th. The stock was sold at an average price of $51.96, for a total value of $16,452,822.24. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,743,212 shares of company stock worth $91,145,351. 29.00% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HQY. Zions Bancorporation purchased a new stake in Healthequity in the 3rd quarter valued at $119,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Healthequity by 105.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,544 shares of the company’s stock valued at $127,000 after purchasing an additional 1,308 shares during the last quarter. Riverhead Capital Management LLC increased its position in shares of Healthequity by 75.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,629 shares of the company’s stock valued at $131,000 after purchasing an additional 1,129 shares during the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of Healthequity by 7.7% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 2,686 shares of the company’s stock valued at $134,000 after purchasing an additional 191 shares during the last quarter. Finally, Fortaleza Asset Management Inc. purchased a new stake in shares of Healthequity during the 2nd quarter valued at $138,000. 98.60% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Healthequity (HQY) Rating Lowered to Sell at BidaskClub” was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.com-unik.info/2017/12/07/healthequity-hqy-rating-lowered-to-sell-at-bidaskclub.html.

About Healthequity

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Analyst Recommendations for Healthequity (NASDAQ:HQY)

What are top analysts saying about Healthequity Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Healthequity Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit